Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26938050 | 0.88 | GALR2 (0.48) | AURKAKMT2AKDRBRAFAURKB | |
| SCHEMBL5389772 | 0.83 | MAPT (0.47) | AURKAKMT2AKDRBRAFAURKB | |
| SCHEMBL5402668 | 0.81 | AURKA (0.48) | AURKAKMT2AKDRBRAFAURKB | |
| SCHEMBL5820813 | 0.81 | NAMPT (0.47) | AURKAKMT2AKDRBRAFAURKB | |
| SCHEMBL5820251 | 0.81 | CYP1A2 (0.45) | AURKAKMT2AKDRBRAFAURKB | |
| SCHEMBL5823423 | 0.81 | AURKA (0.46) | AURKAKMT2AKDRBRAFAURKB | |
| SCHEMBL29091968 | 0.80 | MAPT (0.49) | AURKAKMT2AKDRBRAFAURKB | |
| SCHEMBL5823039 | 0.80 | AURKA (0.50) | AURKAKMT2AKDRBRAFAURKB | |
| SCHEMBL5823980 | 0.80 | ZAP70 (0.49) | AURKAKMT2AKDRBRAFAURKB | |
| SCHEMBL5386316 | 0.79 | SMN1; SMN2 (0.50) | AURKAKMT2ABRAFJAK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276501-B2 | 6-(4-substituted-anilino)pyrimidine derivatives, method for preparation thereof and antiviral pharmaceutical composition comprising the same | B & C BIOPHARM (KR) | 2007-10-02 | — | — | US | disclosed |
| EP-1490358-A4 | 6-(4-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | B & C BIOPHARM (KR) | 2006-04-12 | — | — | EP | disclosed |
| US-20050222150-A1 | 6-(4-substituted-anilino)pyrimidine derivates, method for preparation thereof and antiviral pharmaceutical composition comprising the same | B & C BIOPHARM (KR) | 2005-10-06 | — | — | US | disclosed |
| EP-1490358-A1 | 6-(4-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | B & C Biopharm (KR) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084953-A1 | 6-(4-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | B & C BIOPHARM (KR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222150-A1 | 6-(4-substituted-anilino)pyrimidine derivates, method for preparation thereof and antiviral pharmaceutical composition comprising the same | HAVCR2, NUDT1, GART | AURKA 2144/4885KMT2A 4775/4885KDR 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.